Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 58%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc has demonstrated strong growth in Chromium reaction volumes, indicating a robust market demand for its integrated solutions. Additionally, the company's consumables are projected to significantly outpace instrument revenue growth, with estimates suggesting an increase of 5-19 times by 2027 across its platforms. This combination of increased volumes and strong consumable sales expectations contributes to a positive outlook for the company's financial performance in the evolving life sciences market.

Bears say

10x Genomics has experienced a contraction in 2024, characterized by double-digit pricing pressure impacting revenues and resulting in flat to modestly lower volume sales. The company reported weaker-than-expected Q4 results, missing earnings per share estimates and projecting a full-year revenue outlook below expectations. Furthermore, despite expansion in certain market segments since its peak stock prices in 2021, the growth has not met analyst expectations, leading to a decline of over 90% in stock value during this period.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 58% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.